Immunotheraphy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2
| Autor: | Bubeník J, J. Šimová, Jandlová T |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Interleukin 2
medicine.medical_treatment Immunology Cell Biology Lymphocyte Activation Transfection Mice Tumor Cells Cultured medicine Animals Humans Immunology and Allergy Cytotoxic T cell Mice Inbred BALB C Lymphokine-activated killer cell DNA Neoplasms Experimental Immunotherapy Cytotoxicity Tests Immunologic medicine.disease Recombinant Proteins In vitro Rats Killer Cells Natural Mice Inbred C57BL Cytokine medicine.anatomical_structure Cancer research Interleukin-2 Sarcoma Injections Intraperitoneal Neoplasm Transplantation Plasmacytoma medicine.drug |
| Zdroj: | Immunology Letters. 23:287-292 |
| ISSN: | 0165-2478 |
| DOI: | 10.1016/0165-2478(90)90074-z |
| Popis: | Peritumoral administration of X63-m-IL-2 cells transformed by IL-2 cDNA and constitutively producing large quantities of recombinant IL-2 mediated regression of X63-Ag8.653 plasmocytoma and MC14 sarcoma transplanted in syngeneic mice. Injections of the IL-2-producing cells containing an inserted, modified IL-2 gene effectively inhibited tumour growth also in allogeneic recipients. Activation of murine spleen cells in vitro by co-cultivation with X63-m-IL-2 cells gave rise to lymphokine-activated killer (LAK) cell populations cytotoxic for the X63-Ag8.653 plasmocytoma and MC14 sarcoma. The results suggest that peritumoral administration of lymphoid cells transformed with IL-2 cDNA and constitutively producing IL-2 in the immediate tumour vicinity is sufficient for the effective activation of local IL-2-dependent tumour defence mechanisms and, therefore, can be considered a novel, genetic approach to the immunotherapy of cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|